Stocks and Investing
Stocks and Investing
Thu, March 30, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, March 29, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Ed Arce Maintained (VERA) at Strong Buy with Decreased Target to $11 on, Mar 29th, 2023
Ed Arce of HC Wainwright & Co., Maintained "Vera Therapeutics, Inc." (VERA) at Strong Buy with Decreased Target from $15 to $11 on, Mar 29th, 2023.
Ed has made no other calls on VERA in the last 4 months.
There are 2 other peers that have a rating on VERA. Out of the 2 peers that are also analyzing VERA, all agree with Ed's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Laura Chico of "Wedbush" Downgraded from Buy to Hold and Held Target at $8 on, Wednesday, January 4th, 2023
- Maury Raycroft of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $6 on, Wednesday, January 4th, 2023
Contributing Sources